Inhibikase Therapeutics is a clinical-stage company developing small molecule kinase inhibitors for cardiopulmonary diseases. Its lead program IkT-001, a prodrug formulation of imatinib, targets pulmonary arterial hypertension. The company has shifted emphasis from earlier neurodegenerative disease programs to this orphan cardiopulmonary indication.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -9.9 | — |
| Q3 2025 | 0 | — | -11.9 | — |
| Q4 2025 | 0 | — | -12.7 | — |
| Q1 2026 | 0 | — | -16.4 | — |
| Q2 2026 | 0 | — | -19.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: SAB Biotherapeutics, Inc. (SABS), Global Water Resources, Inc. (GWRS), ProQR Therapeutics N.V. (PRQR), Crown Reserve Acquisition Corp. I (CRAC), Alliance Entertainment Holding Corporation (AENT), BitFuFu Inc. (FUFU)